

Literatura ACTA MEDICINAE

4/2021 Kazuistiky v onkologii, hematoonkologii a hematologii

- 3 **Dlouhodobá remise při léčbě enzalutamidem ve druhé linii léčby pacienta s metastatickým kastročně rezistentním karcinomem prostaty**
MUDr. Jiří Navrátil, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno
- 3 **Virtuální WCLC 2020 a imunoterapie – zpráva z konference**
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 3 **Atezolizumab v léčbě metastatického adenokarcinomu plic**
MUDr. Juraj Kultán Klinika plicních nemocí a tuberkulózy, FN a LF UP, Olomouc
- 3 **Atezolizumab a bevacizumab v léčbě hepatocelulárního karcinomu**
MUDr. Beatrix Bencsiková, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 3 **Hepatocelulární karcinom a cílená terapie**
MUDr. Aleš Langer | MUDr. Hana Študentová, Ph.D. Onkologická klinika LF UP a FN Olomouc
- 3 **Atezolizumab v léčbě uroteliálního karcinomu**
MUDr. Michaela Matoušková Urocentrum Praha, Onkologická klinika FTN a 1. LF UK, Praha
doc. MUDr. Tomáš Büchler, Ph.D. | Ing. Jaroslava Skálová Onkologická klinika FTN a 1. LF UK, Praha
- 4 **Atezolizumab v léčbě metastatického karcinomu ledvinné pánvičky, kazuistika pacienta s dlouhodobou léčebnou odpovědí**
doc. MUDr. Alexandr Poprach, Ph.D. Klinika komplexní onkologické péče a Lékařská fakulta Masarykovy univerzity, Brno
MUDr. Kateřina Stískalová Oddělení radiologie (ORDG) MOÚ, Brno
doc. MUDr. Michal Staník, Ph.D. Oddělení urologické onkologie (OURO) MOÚ, Brno
- 4 **Ovlivní Phesgo (kombinace pertuzumabu a trastuzumabu) péči o pacientky s HER2 pozitivním karcinomem prsu? Novinky v léčbě**
MUDr. Lenka Rušínová | doc. MUDr. Renata Soumarová, Ph.D. Radioterapeutická a onkologická klinika 3. LF UK a FN Královské Vinohrady, Praha
- 4 **Domácí parenterální výživa v praxi**
MUDr. Štěpán Tuček, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno, Interní hematologická a onkologická klinika FN Brno
- 4 **Mutace genu *SDHD* v rodině s výskytem paragangliomu krku**
Mgr. Zdeněk Musil, Ph.D. Ústav biologie a lékařské genetiky, 1. LF UK a VFN, Praha
RNDr. Ing. Libor Staněk, Ph.D. Laboratoř Praha, CUBE, synlab czech, s. r. o., Chirurgická klinika, 3. LF UK a FNKV, Praha
prof. MUDr. Jan Betka, DrSc. Klinika ORL a chirurgie hlavy a krku, 1. LF UK a FN v Motole, Praha
prof. MUDr. Jaroslava Dušková, CSc. Ústav patologie, 1. LF UK a VFN, Praha
prof. MUDr. Tomáš Zelinka, CSc. Klinika otolaryngologická, 3. LF UK a FNKV, Praha
doc. MUDr. Martin Chovanec, Ph.D. | MUDr. Anasuya Guha II. interní klinika 1. LF UK a VFN, Praha
MUDr. Aleš Vícha, Ph.D. Klinika dětské onkologie, 2. LF UK a FN v Motole, Praha
- 5 **Současný pohled na stanovení prognózy u pacientů s folikulárním lymfomem**
MUDr. Aleš Obr, Ph. D. Hemato-onkologická klinika Lékařské fakulty Univerzity Palackého a Fakultní nemocnice Olomouc
- 5 **Léčba brentuximab vedotinem u pacientky s refrakterním systémovým Hodgkinovým lymfomem a sekundárním postižením CNS**
MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FN Královské Vinohrady a 3. LF UK, Praha, Česká skupina Hodgkinův lymfom, z. s.
- 5 **Léčba primárně splenického lymfomu bez vilózních lymfocytů s leukemizací**
MUDr. Ivana Zubatá Karlová | MUDr. Kateřina Beníšková | doc. MUDr. Jan Novák, Ph.D. | MUDr. Barbora Bačová
Hematologická klinika, 3. LF UK a FNKV, Praha

- 5 **Castlemanova nemoc – neinfekční a nemaligní lymfadenopatie se zvýšenou koncentrací polyklonálních imunoglobulinů a systémovými zánětlivými projevy – diagnostika a léčba**
prof. MUDr. Zdeněk Adam, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno
MUDr. Zuzana Adamová, Ph.D. Chirurgické oddělení, Vsetínská Nemocnice, a. s.
prof. MUDr. Luděk Pour, Ph.D. | prof. MUDr. Marta Krejčí, Ph.D. | MUDr. Zdeněk Král, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno
- 6 **Zkušenosti s preparátem Adynovi**
MUDr. Gabriela Romanová Oddělení klinické hematologie FN Brno, Lékařská fakulta Masarykovy univerzity, Brno
- 7 **Eltrombopag ve druhé linii léčby u pacienta s chronickou imunitní trombocytopenií**
MUDr. Miroslav Genský Oddělení klinické hematologie, Krajská nemocnice Liberec, a. s.
- 7 **Léčba ravulizumabem v klinické praxi**
MUDr. Libor Červinek, Ph.D. Interní hematologická a onkologická klinika Fakultní nemocnice Brno
- 7 **První zkušenosti s náhradou ecilizumabu ravulizumabem v léčbě klasické paroxysmální noční hemoglobinurie**
MUDr. Jaromír Gumulec Klinika hematoonkologie FN Ostrava a Lékařské fakulty Ostravské univerzity
MUDr. Radomíra Hrdličková Klinika hematoonkologie FN Ostrava a Lékařské fakulty Ostravské univerzity, Krevní centrum FN Ostrava
Mgr. Jan Martinek Zdravotní ústav se sídlem v Ostravě
- 7 **Podávání ecilizumabu v těhotenství**
MUDr. Jan Válka, Ph.D. | prof. MUDr. Jaroslav Čermák, CSc. Ústav hematologie a krevní transfuze, Praha
- 8 **Erdheimova-Chesterova choroba – zánětlivé projevy, které indukuje maligní choroba – diagnostika a léčba**
prof. MUDr. Zdeněk Adam, CSc. | prof. MUDr. Marta Krejčí, Ph.D. | prof. MUDr. Luděk Pour, Ph.D. | MUDr. Martin Krejčí | MUDr. Martin Štork, Ph.D. | MUDr. Zdeněk Král, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno
doc. MUDr. Zdeněk Řehák, Ph.D. | MUDr. Renata Koukalová Oddělení nukleární medicíny, Masarykův onkologický ústav, Brno
doc. RNDr. Sabina Ševčíková, Ph.D. Ústav patologické fyziologie LF MU a FN Brno
MUDr. Tomáš Nebeský, CSc. Klinika zobrazovacích metod LF MU a FN Brno
MUDr. Zuzana Adamová, Ph.D. Chirurgické oddělení, Vsetínská nemocnice

Dlouhodobá remise při léčbě enzalutamidem ve druhé linii léčby pacienta s metastatickým kastročně rezistentním karcinomem prostaty

MUDr. Jiří Navrátil, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno

- 1 Scher, I. H. – Fizazi, K. – Saad, F., et al.: Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med*, 2012, 367, s. 1187–1197.
- 2 Tannock, F. I. – de Wit, R. – Berry, R. W., et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med*, 2004, 351, s. 1502–1512.

Virtuální WCLC 2020 a imunoterapie – zpráva z konference

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- 1 Gray, J. E. – Rodríguez-Abreu, D. – Powell, S. F., et al.: Pembrolizumab + pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189. Prezentováno na: 2020 World Conference on Lung Cancer Singapore. 27–31. 1. 2021, abstrakt FP13.02.
- 2 Boyer, M. – Mehmet – Şendur, M. A. N., et al.: Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%: randomized, double-blind phase III KEYNOTE-598 study. *J Clin Oncol*, 29. 1. 2021, DOI: 10.1200/JCO.20.03579.
- 3 Reck, M. – Lee, K. H. – Frost, N., et al.: Pembrolizumab plus platinum chemotherapy and radiotherapy in unresectable, locally advanced, stage III NSCLC: KEYNOTE-799. Prezentováno na: International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC) Singapore. 28–31. 1. 2021, abstrakt OA02.03.
- 4 Sezer, A. – Kilickap, S. – Gümüş, M., et al.: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet*, 2021, 397, s. 592–604, DOI: [https://doi.org/10.1016/S0140-6736\(21\)00228-2](https://doi.org/10.1016/S0140-6736(21)00228-2).
- 5 Lee, J. M. – Chaft, J. – Nicholas, A., et al.: Surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB-IIIb NSCLC: LCMC 3 trial primary analysis. Prezentováno na: 2020 World Conference on Lung Cancer Singapore. 28–31. 1. 2021, abstrakt 3195.
- 6 Baas, P. – Scherpereel, A. – Nowak, A. K., et al.: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. *Lancet*, 2021, 397, s. 375–386.
- 7 Ottensmeier, F. D. – Califano, R., et al.: Nivolumab versus placebo in relapsed malignant mesothelioma: preliminary results from the CONFIRM phase 3 trial. Prezentováno na: International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer. 28–31. 1. 2021, abstrakt P501.11.

Atezolizumab v léčbě metastatického adenokarcinomu plic

MUDr. Juraj Kultán Klinika plicních nemocí a tuberkulózy, FN a LF UP, Olomouc

- 1 Ústav zdravotnických informací a statistiky ČR. Epidemiologie zhoubných novotvarů v České republice. Dostupné z: <https://www.uzis.cz/katalog/zdravotnicka-statistika/novotvary>, vyhledáno 20. 4. 2021.
- 2 Howlander, N. – Noone, A. M. – Krapcho, M., et al.: SEER Cancer Statistics Review (CSR) 1975–2018. *Cancer Statistics Review, 1975–2018*. Dostupné z: https://seer.cancer.gov/csr/1975_2018/, vyhledáno v dubnu 2021.
- 3 Rittmeyer, A. – Barlesi, F. – Waterkamp, D., et al.: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*, 2017, 389, s. 255–265.
- 4 Fehrenbacher, L. – von Pawel, J. – Park, K., et al.: Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer. *J Thorac Oncol*, 2018, 13, s. 1156–1170.
- 5 Meoni, G. – Decarli, N. L. – Benucci, M., et al.: Pseudoprogression in lung cancer: a case report. *Explor Target Antitumor Ther*, 2020, 1, s. 372–380.
- 6 SPC přípravku Nimesil, datum revize textu 10. 10. 2017.
- 7 Zahir, M. N. – Masood, N. – Shabbir-Moosajee, M.: Cisplatin-induced posterior reversible encephalopathy syndrome and successful re-treatment in a patient with non-seminomatous germ cell tumor: a case report. *J Med Case Rep*, 2012, 6, s. 409.
- 8 Lee, E. Q. – Drews, R. E. – Wen, P. Y.: Overview of neurologic complications of platinum-based chemotherapy. Dostupné z: <https://www.uptodate.com/contents/overview-of-neurologic-complications-of-platinum-based-chemotherapy>, vyhledáno 23. 4. 2021.

Atezolizumab a bevacizumab v léčbě hepatocelulárního karcinomu

MUDr. Beatrix Bencsiková, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- 1 Globocan 2012. Dostupné z: http://globocan.iarc.fr/Pages/facts_sheets_population.aspx, vyhledáno 26. 4. 2021.
- 2 Knox, J. J. – Cleary, S. P. – Dawson, L. A.: Localized and systemic approaches to treating hepatocellular carcinoma. *J Clin Oncol*, 2015, 33, s. 1835–1844.
- 3 Motz, G. T. – Santoro, S. P. – Wang, L. P., et al.: 3. Tumor endothelium FAsL establishes a selective immune barrier promoting tolerance in tumors. *Nat Med*, 2014, 20, s. 607–615.
- 4 Finn, S., et al.: 4. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*, 2020, 382, s. 1894–1905.
- 5 eUpdate – Hepatocellular Carcinoma Treatment Recommendations. 19. 6. 2020. ESMO Guidelines Committee.
- 6 NCCN Guidelines version 5.2020 Hepatocellular Carcinoma, www.nccn.org.

Hepatocelulární karcinom a cílená terapie

MUDr. Aleš Langer | MUDr. Hana Študentová, Ph.D. Onkologická klinika LF UP a FN Olomouc

- 1 Singal, A. G. – Lampertico, P. – Nahon, P.: Epidemiology and surveillance for hepatocellular carcinoma: New trends. *J Hepatol*, 2020, 2, s. 250–261.
- 2 Llovet, J. M. – Ricci, S. – Mazzaferro, V.: Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*, 2008, 4, s. 378–390.
- 3 Kudo, M. – Finn, R. S. – Qin, S.: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet*, 2018, 10126, s. 1163–1173.
- 4 Finn, R. S. – Shukui, Q. I. N. – Ikeda, M.: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*, 2020, 382, s. 1894–1905.
- 5 Bruix, J. – Qin, S. – Merle, P.: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2017, 10064, s. 56–66.
- 6 Abou-Alfa, G. K. – Meyer, T. – Cheng, A.-L.: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *N Engl J Med*, 2018, 1, s. 54–63.
- 7 Zhu, A. X. – Kang, Y.-K. – Yen, Ch.-J.: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncology*, 2019, 2, s. 282–296.

Atezolizumab v léčbě uroteliálního karcinomu

MUDr. Michaela Matoušková Urocentrum Praha, Onkologická klinika FTN a 1. LF UK, Praha

doc. MUDr. Tomáš Büchler, Ph.D. | Ing. Jaroslava Skálová Onkologická klinika FTN a 1. LF UK, Praha

- 1 Balar, A. V. – Galsky, M. D. – Rosenberg, J. E., et al.: IMvigor210 Study Group: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet*, 2017, 389, s. 67–76.
- 2 Powles, T. – Park, S. H. – Voog, E., et al.: Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. *J Clin Oncol*, 2020, 38, suppl. 18, DOI: 10.1200/JCO.2020.38.18_suppl.LBA1.
- 3 Sternberg, C. N. – Loriot, Y. – James, N., et al.: Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or non urothelial carcinoma of the urinary tract. *Eur Urol*, 2019, 76, s. 73–81.

Atezolizumab v léčbě metastatického karcinomu ledvinné pánvičky, kazuistika pacienta s dlouhodobou léčebnou odpovědí

doc. MUDr. Alexandr Poprach, Ph.D. Klinika komplexní onkologické péče a Lékařská fakulta Masarykovy univerzity, Brno

MUDr. Kateřina Stískalová Oddělení radiologie (ORDG) MOÚ, Brno

doc. MUDr. Michal Staník, Ph.D. Oddělení urologické onkologie (OURO) MOÚ, Brno

- 1 Balar, A. V. – Galsky, M. D. – Rosenberg, J. E., et al.: IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet*, 2017, 389, s. 67–76.
- 2 Rosenberg, J. E. – Hoffman-Censits, J. – Powles, T., et al.: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet*, 2016, 387, s. 1909–1920.
- 3 Powles, T. – Durán, I. – van der Heijden, M. S., et al.: Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*, 2018, 391, s. 748–757.

Ovlivní Phesgo (kombinace pertuzumabu a trastuzumabu) péči o pacientky s HER2 pozitivním karcinomem prsu? Novinky v léčbě

MUDr. Lenka Rušinová | doc. MUDr. Renata Soumarová, Ph.D. Radioterapeutická a onkologická klinika 3. LF UK a FN Královské Vinohrady, Praha

- 1 Ross, J. S. – Slodkowska, E. A. – Symmans, W. F., et al.: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. *Oncologist*, 2009, 14, s. 320–368.
- 2 Nahta, R. – Hung, M. C. – Esteva, F. J.: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. *Cancer Res*, 2004, 64, s. 2343–2346.
- 3 Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13, s. 25–32.
- 4 Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet Oncol*, 2016, 17, s. 791–800.
- 5 Swain, S. M., et al.: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol*, 2013, 14, s. 461–471.
- 6 Modrá kniha COS ČLS JEP. Aktualizace: 27. Brno, Masarykův onkologický ústav.
- 7 Jackisch, C. – Stroyakovskiy, D. – Pivot, X., et al.: Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: final analysis from the phase III, open-label, randomized HannahH study. *Cancer Res*, 2017, 78, 4, suppl.
- 8 Bookbinder, L. H. – Hofer, A. – Haller, M. F., et al.: A recombinant human enzyme for enhanced interstitial transport of therapeutics. *J Control Release*, 2006, 114, s. 230–241.
- 9 Tan, A. R. – Im, S. A. – Mattar, A., et al.: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. *Lancet Oncol*, 2021, 22, s. 85–97.
- 10 Schneeweiss, A. – Chia, S. – Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). *Ann Oncol*, 2013, 24, s. 2278–2284.
- 11 Swain, S. – Ewer, M., et al.: Pertuzumab, trastuzumab, and standard anthracycline-and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. *Ann Oncol*, 2017, 29, s. 646–653.
- 12 O'Shaughnessy, J. – Sousa, S. – Cruz, J., et al.: Patient (pt) preference for the pertuzumab–trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): primary analysis of the open-label, randomised crossover PHrance5-Ca study. *Ann Oncol*, 2020, 31, s. S306–S307.

Domácí parenterální výživa v praxi

MUDr. Štěpán Tuček, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno, Interní hematologická a onkologická klinika FN Brno

- 1 Kotlířková, E. – Křemen, J.: Domácí parenterální výživa. *Interní Med*, 2008, 10, s. 76–79.
- 2 Gojda, J.: Syndrom krátkého stěva, analýza registru REDNUP, XXXVI. mezinárodní kongres SKVIMP, Hradec Králové, 11. 9. 2020.
- 3 Centra domácí parenterální výživy. Dostupné z: <http://www.skvimp.cz/pracovni-skupiny/domaci-parentalni-vyziva/>
- 4 Život bez stěva, www.zivotbezsteva.cz, vyhledáno 10. 3. 2021.
- 5 XXXVI. Mezinárodní kongres SKVIMP. Dostupné z: <http://www.skvimp.cz/kongresy/xxxvi-mezinarodni-kongres-skvimp-2020/>, vyhledáno 10. 3. 2021.
- 6 Bond, A. – Teubner, A., et al.: A novel discharge pathway for patients with advanced cancer requiring home parenteral nutrition. *J Hum Nutr Diet*, 2019, 32, s. 492–500.
- 7 Rosania, R. – Chiapponi, C. – Malfertheiner, P. – Venerito, M.: Nutrition in patients with gastric cancer: an update. *Gastrointest Tumors*, 2016, 2, s. 178–187.

Mutace genu SDHD v rodině s výskytem paragangliomu krku

Mgr. Zdeněk Musil, Ph.D. Ústav biologie a lékařské genetiky, 1. LF UK a VFN, Praha

RNDr. Ing. Libor Staněk, Ph.D. Laboratoř Praha, CUBE, synlab czech, s. r. o., Chirurgická klinika, 3. LF UK a FNKV, Praha

prof. MUDr. Jan Betka, DrSc. Klinika ORL a chirurgie hlavy a krku, 1. LF UK a FN v Motole, Praha

prof. MUDr. Jaroslava Dušková, CSc. Ústav patologie, 1. LF UK a VFN, Praha

prof. MUDr. Tomáš Zelinka, CSc. Klinika otolaryngologická, 3. LF UK a FNKV, Praha

doc. MUDr. Martin Chovanec, Ph.D. | MUDr. Anasuya Guha II. interní klinika 1. LF UK a VFN, Praha

MUDr. Aleš Vícha, Ph.D. Klinika dětské onkologie, 2. LF UK a FN v Motole, Praha

- 1 Martínez-Reyes I. – Chandel, N. S.: Mitochondrial TCA cycle metabolites control physiology and disease. *Nature Communications*, 2020, 11, 102.
- 2 Aldera, A. P. – Govender, D. J.: Gene of the month: SDH. *Clin Pathol*, 2018, 71, s. 95–97.
- 3 Settas, N. – Fauz, F. R. – Stratakis, C. A.: Succinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome. *Mol Cell Endocrinol*, 2018, 469, s. 107–111.
- 4 Vícha, A. – Taieb, D. – Pacak, K.: Current views on cell metabolism in SDH-related pheochromocytoma and paraganglioma. *Endocr Relat Cancer*, 2014, 21, s. R261–R277.
- 5 Guha, A. – Musil, Z. – Vícha, A., et al.: A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas. *Neoplasma*, 2019, 66, s. 671–680.
- 6 Vícha, A. – Musil, Z. – Pacak, K.: Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. *Curr Opin Endocrinol Diabetes Obes*, 2013, 20, s. 186–191.
- 7 MacFarlane, J. – Seong, K. C. – Bisambar, C., et al.: A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond pheochromocytoma and paraganglioma. *Clin Endocrinol*, 2020, 93, s. 528–538.
- 8 Braun, S. – Riemann, K. – Pusch, C. M., et al.: Paraganglioma in the area of the head and neck. A review of molecular genetic research. *HNO*, 2004, 52, s. 11–17.
- 9 Vícha, A. – Holzerova, M. – Krepelova, A., et al.: Molecular cytogenetic characterization in four pediatric pheochromocytomas and paragangliomas. *Pathol Oncol Res*, 2011, 17, s. 801–808.
- 10 Majewska, A. – Budny, B. – Ziernicka, K., et al.: Head and neck paragangliomas – a genetic overview. *Int J Mol Sci*, 2020, 21, s. 7669.
- 11 Musil, Z. – Puchmajerová, A. – Krepelová, A., et al.: Paraganglioma in a 13-year-old girl: a novel SDHB gene mutation in the family? *Cancer Genet Cytogenet*, 2010, 197, s. 189–192.
- 12 Lee, H. – Jeong, S. – Yu, Y., et al.: Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: a systematic review and updated meta-analysis. *J Med Genet*, 2020, 57, s. 217–225.
- 13 Riemann, K. – Sotlar, K. – Kupka, S., et al.: Chromosome 11 monosomy in conjunction with a mutated SDHD initiation codon in non-familial paraganglioma cases. *Cancer Genet Cytogenet*, 2004, 150, s. 128–135.

14 Braun, S. – Riemann, K. – Kupka, S., et al.: Active succinate dehydrogenase (SDH) and lack of SDHD mutations in

sporadic paragangliomas. *Anticancer Res*, 2005, 25, s. 2809–2814.
15 Lenders, J.W. – Duh, Q.Y. – Eisenhofer, G., et al.: Pheochromocytoma

and paraganglioma: an endocrine society clinical practice guideline. *Endocrine Society. J Clin Endocrinol Metab*, 2014, 99, s. 1915–1942.

Současný pohled na stanovení prognózy u pacientů s folikulárním lymfomem

MUDr. Aleš Obr, Ph. D. Hemato-onkologická klinika Lékařské fakulty Univerzity Palackého a Fakultní nemocnice Olomouc

- 1 Belada, D. – Trněný, M., et al.: *Diagnostické a léčebné postupy u nemocných s maligními lymfomy*. Praha, KAP CZ, 2020.
- 2 Tan, D. – Horning, S. J. – Hoppe, R. T. – Levy, R., et al.: Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. *Blood*, 2013, 122, s. 981–987.
- 3 Janikova, A. – Bortlice, Z. – Campr, V., et al.: Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database. *Leukemia & Lymphoma*, 2016, 57, s. 1094–1103.
- 4 Solal-Celigny, P.: Follicular Lymphoma International Prognostic Index. *Blood*, 2004, 104, s. 1258–1265.
- 5 Janikova, A. – Bortlice, Z. – Campr, V., et al.: The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. *Ann Hematol*, 2018, 97, s. 669–678.
- 6 Carbone, P. P. – Kaplan, H. S. – Musshoff, K., et al.: Smithers Report of the Committee on Hodgkin's Disease Staging Classification. *Cancer Res*, 1971, 31, s. 1860–1861.
- 7 A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med*, 1993, 329, s. 987–994.
- 8 Sehn, L. H. – Berry, B. – Chhanabhai, M., et al.: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood*, 2007, 109, s. 1857–1861.
- 9 van de Schans, S. A. M. – Steyerberg, E. W. – Nijziel, M. R., et al.: Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. *Ann Oncol*, 2009, 20, s. 1697–1702.
- 10 Montoto, S. – López-Guillermo, A. – Altés, A., et al.: Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. *Ann Oncol*, 2004, 15, s. 1484–1489.
- 11 Casulo, C. – Byrtek, M. – Dawson, K. L., et al.: Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. *JCO*, 2015, 33, s. 2516–2522.
- 12 Dave, S. S. – Wright, G. – Tan, B., et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *N Engl J Med*, 2004, 351, s. 2159–2169.
- 13 Smith, S. M.: Dissecting follicular lymphoma: high versus low risk. *Hematology*, 2013, 2013, s. 561–567.
- 14 Pastore, A. – Jurinovic, V. – Kridel, R., et al.: Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. *Lancet Oncol*, 2015, 16, s. 1111–1122.
- 15 Lockmer, S. – Ren, W. – Brodtkorb, M., et al.: M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemotherapy. *Br J Haematol*, 2020, 188, s. 259–267.
- 16 Jurinovic, V. – Kridel, R. – Staiger, A. M., et al.: Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. *Blood*, 2016, 128, s. 1112–1120.
- 17 Bachy, E. – Maurer, M. J. – Habermann, T. M., et al.: A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. *Blood*, 2018, 132, s. 49–58.
- 18 Rummel, M. J. – Niederle, N. – Maschmeyer, G., et al.: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*, 2013, 381, s. 1203–1210.
- 19 Mir, F. – Mattiello, F. – Grigg, A., et al.: Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. *Am J Hematol*, 2020, 95, s. 1503–1510.

Léčba brentuximab vedotinem u pacientky s refrakterním systémovým Hodgkinovým lymfomem a sekundárním postižením CNS

MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FN Královské Vinohrady a 3. LF UK, Praha, Česká skupina Hodgkinův lymfom, z. s.

- 1 Cheah, C. Y. – Bröckelmann, P. J. – Chihara, D., et al.: Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. *Am J Hematol*, 2016, 91, s. 894–899.
- 2 Gerstner, E. R. – Abrey, L. E. – Schiff, D., et al.: CNS Hodgkin lymphoma. *Blood*, 2008, 112, s. 1658–1661.
- 3 LaCasce, A. S. – Bociek, R. G. – Sawas, A., et al.: Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. *Blood*, 2018, 132, s. 40–48.
- 4 Abid, M. B. – Wang, S. – Loi, H. Y., et al.: ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. *Ann Hematol*, 2016, 95, s. 1725–1726.
- 5 Mitsunobu, T. – Nishikawa, T. – Kusuda, M., et al.: Brentuximab vedotin and high-dose methotrexate administered alternately for refractory anaplastic large-cell lymphoma with central nervous system disease. *J Pediatr Hematol Oncol*, 2020, 42, s. e456–e458.
- 6 Dela Cruz, W. P. – Setlik, R. – Hassantoufighi, A., et al.: Novel brentuximab vedotin combination therapies show promising activity in highly refractory CD30+ non-hodgkin lymphoma: A case series and review of the literature. *Case Reports in Oncological Medicine*, 2016, 9980, s. 1–7.
- 7 Chamberlain, M. C.: Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. *J Neurooncol*, 2014, 118, s. 155–162.
- 8 Shah, G. D. – Yahalom, J. – Correa, D. D., et al.: Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. *J Clin Oncol*, 2007, 25, s. 4730–4735.
- 9 Ferreri, A. J. M. – Cwynarski, K. – Pulczynski, E., et al.: Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. *Lancet Haematol*, 2017, 4, s. 510–523.
- 10 Moskowitz, C. H. – Walewski, J. – Nademanee, A., et al.: Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. *Blood*, 2018, 132, s. 2639–2642.
- 11 Ansell, S. M. – Lesokhin, A. M. – Borrello, I., et al.: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*, 2015, 372, s. 311–319.
- 12 Nayak, L. – Iwamoto, F. M. – LaCasce, A., et al.: PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. *Blood*, 2017, 129, s. 3071–3073.

Léčba primárně splenického lymfomu bez vilózních lymfocytů s leukemizací

MUDr. Ivana Zubatá Karlová | MUDr. Kateřina Beníšková | doc. MUDr. Jan Novák, Ph.D. | MUDr. Barbora Bačová
Hematologická klinika, 3. LF UK a FNKV, Praha

1 Dostupné z: http://www.kardioccz.cz/data/upload/doporučene_postupy/2017/Souhrn_Odborneho_stanoviska_ESC_jak_ovlivnit_kardiovaskularni_toxicitu_provazejici_lecbu_nadorovych_onemocneni.pdf, vyhledáno 19. 4. 2021.

Castlemanova nemoc – neinfekční a nemaligní lymfadenopatie se zvýšenou koncentrací polyklonálních imunoglobulinů a systémovými zánětlivými projevy – diagnostika a léčba

prof. MUDr. Zdeněk Adam, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno

MUDr. Zuzana Adamová, Ph.D. Chirurgické oddělení, Vsetínská Nemocnice, a. s.

prof. MUDr. Luděk Pour, Ph.D. | prof. MUDr. Marta Krejčí, Ph.D. | MUDr. Zdeněk Král, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno

- 1 Fajgenbaum, D. C. – Shilling, D.: Castleman disease pathogenesis. *Hematol Oncol Clin North Amer*, 2018, 32, s. 11–21.
- 2 Simpson, D.: Epidemiology of Castleman disease. *Hematol Oncol Clin North Am*, 2018, 32, s. 1–10.
- 3 Dispenzieri, A. – Armitage, J. O. – Loes, M. J., et al.: The clinical spectrum of Castleman's disease. *Amer J Hematol*, 2012, 87, s. 997–1002.
- 4 Fajgenbaum, D. C. – Uldrick, T. S. – Bagg, A., et al.: International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. *Blood*, 2017, 129, s. 1646–1657.

- 5 Kawabata, H. – Kadowaki, N. – Nishikori, M., et al.: Clinical features and treatment of multicentric Castleman's disease: a retrospective study of 21 Japanese patients at a single institute. *J Clin Exp Hematol*, 2013, 53, s. 69–77.
- 6 Masaki, Y. – Kawabata, H. – Takai, K., et al.: Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. *Int J Hematol*, 2016, 103, s. 686–692.
- 7 van Rhee, F. – Greenway, A. – Stone, K.: Treatment of idiopathic Castleman disease. *Hematol Oncol Clin North Amer*, 2018, 32, s. 89–106.
- 8 Van Rhee, F. – Voorhees, P. – Dispenzieri, A., et al.: International evidence based consensus treatment guidelines for idiopathic multicentric Castleman disease. *Blood*, 2018, 132, s. 2115–2124.
- 9 Herrada, J. – Cabanillas, F. – Rice, L., et al.: The clinical behavior of localized and multicentric Castleman disease. *Ann Intern Med*, 1998, 128, s. 657–662.
- 10 Chronowski, G. M. – Ha, C. S. – Wilder, R. B., et al.: Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. *Cancer*, 2001, 92, s. 670–676.
- 11 Zhu, S. H. – Yu, Y. H. – Zhang, Y., et al.: Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients. *Med Oncol*, 2013, 30, s. 492–498.
- 12 Liu, A. Y. – Nabel, C. S. – Finkelman, B. S., et al.: Idiopathic multicentric Castleman's disease: a systematic literature review. *Lancet Haematol*, 2016, 3, s. e163–e175.
- 13 Peker, D. – Martinez, A. E. – Schwartz, M. A., et al.: Complete remission in 4 patients with human herpesvirus 8-associated multicentric Castleman disease using rituximab and liposomal doxorubicin, a novel chemotherapy combination. *Clin Adv Hematol Oncol*, 2012, 10, s. 204–206.
- 14 Hoffmann, C. – Schmid, H. – Müller, M., et al.: Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. *Blood*, 2011, 118, s. 3499–3503.
- 15 Fragasso, A. – Mannarella, C. – Ciancio, A., et al.: Complete remission and virologic response to combined chemioimmunotherapy (R-CVP) followed by rituximab maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman disease. *Leuk Lymphoma*, 2008, 49, s. 2224–2226.
- 16 Casquero, A. – Barroso, A. – Fernández Guerrero, M. L.: Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. *Ann Hematol*, 2006, 85, s. 185–187.
- 17 Ide, M. – Kawachi, Y. – Izumi, Y., et al.: Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. *Eur J Haematol*, 2006, 76, s. 119–123.
- 18 Powles, T. – Stebbing, J. – Montoto, S., et al.: Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. *Blood*, 2007, 110, s. 4132–4133.
- 19 Bestawros, A. – Michel, R. – Séguin, C., et al.: Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. *Am J Hematol*, 2008, 83, s. 508–511.
- 20 Buchler, T. – Dubash, S. – Lee, V., et al.: Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases. *AIDS*, 2008, 22, s. 1685–1687.
- 21 Bower, M. – Veraitch, O. – Szydlowski, R., et al.: Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. *Blood*, 2009, 113, s. 4521–4524.
- 22 Mian, H. – Leber, B.: Mixed variant multicentric Castleman disease treated with rituximab: case report. *J Pediatr Hematol Oncol*, 2010, 32, s. 622.
- 23 Lee, J. P. – Kim, D. K. – Oh, D. Y.: Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid. *Clin Nephrol*, 2011, 75, s. 165–170.
- 24 Gérard, L. – Bérezné, A. – Galcier, L., et al.: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 Castleman Trial. *J Clin Oncol*, 2007, 25, s. 3350–3356.
- 25 Gérard, L. – Michot, J. M. – Burcheri, S., et al.: Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. *Blood*, 2012, 119, s. 2228–2233.
- 26 Ramasamy, K. – Gandhi, S. – Flowers, M. T., et al.: Rituximab and thalidomide combination therapy for Castleman disease. *Brit J Haematol*, 2012, 158, s. 415–429.
- 27 Stary, G. – Kohrgruber, N. – Herneth, A. M., et al.: Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide. *AIDS*, 2008, 22, s. 1232–1234.
- 28 Lee, F. C. – Merchant, S. H.: Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. *Am J Hematol*, 2003, 73, s. 48–53.
- 29 Starkey, C. R. – Joste, N. E. – Lee, F. C.: Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. *Am J Hematol*, 2006, 81, s. 303–304.
- 30 Kim, S. Y. – Lee, S. A. – Ryoo, H. M., et al.: Thalidomide for POEMS syndrome. *Ann Hematol*, 2006, 85, s. 545–546.
- 31 Wang, X. – Ye, S. – Xiong, C., et al.: Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease. *Jpn J Clin Oncol*, 2011, 41, s. 1221–1224.
- 32 Menegato, M. A. – Canelles, M. F. – Tonutti, E., et al.: Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. *Clin Nephrol*, 2004, 61, s. 352–356.
- 33 Miltenyi, Z. – Toth, J. – Gonda, A., et al.: Successful immunomodulatory therapy in Castleman disease with paraneoplastic pemphigus vulgaris. *Pathol Oncol Res*, 2009, 15, s. 375–381.
- 34 Zhao, X. – Shi, R. – Jin, X., et al.: Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases. *J Am Acad Dermatol*, 2011, 65, s. 430–432.
- 35 Jung, C. P. – Emmerich, B. – Goebel, F. D., et al.: Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. *Am J Hematol*, 2004, 75, s. 176–177.
- 36 Hess, G. – Wagner, V. – Kreft, A., et al.: Effects of bortezomib on proinflammatory cytokine levels and transfusion dependency in patient with multicentric Castleman disease. *Brit J Haematol*, 2006, 134, s. 602–605.
- 37 Sobas, M. A. – Alonso Vence, N. – Diaz Arias, J., et al.: Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to POEMS syndrome (MCD-POEMS variant). *Ann Hematol*, 2010, 89, s. 217–219.
- 38 Yoshizaki, K. – Murayama, S. – Ito, H., et al.: The role of interleukin-6 in Castleman disease. *Hematol Oncol Clin North Amer*, 2018, 32, s. 23–36.
- 39 Galeotti, C. – Boucheron, A. – Guillaume, S., et al.: Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody. *Mol Cancer Ther*, 2012, 11, s. 1623–1626.
- 40 Yuzuriha, A. – Saitoh, T. – Koiso, H., et al.: Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. *Acta Haematol*, 2011, 126, s. 147–150.
- 41 Higuchi, T. – Nakanishi, T. – Takada, K., et al.: A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab. *J Korean Med Sci*, 2010, 25, s. 1364–1367.
- 42 Arita, Y. – Sakata, Y. – Sudo, T., et al.: The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease. *Heart Vessels*, 2010, 25, s. 444–447.
- 43 Song, S. N. – Tomosugi, N. – Kawabata, H., et al.: Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. *Blood*, 2010, 116, s. 3627–3634.
- 44 Nishimoto, N. – Terao, K. – Mima, T., et al.: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. *Blood*, 2008, 112, s. 3959–3964.
- 45 Williams, S. C.: First IL-6-blocking drug nears approval for rare blood disorder. *Nat Med*, 2013, 19, s. 1193.
- 46 Robey, R. C. – Mletzko, S. – Colley, C., et al.: The use of monoclonal antibodies to treat Castleman's disease. *Immunotherapy*, 2014, 6, s. 211–219.
- 47 Nagai, K. – Ueda, A. – Yamagata, K.: Successful use of tocilizumab in a case of multicentric Castleman's disease and end-stage renal disease. *Ther Apher Dial*, 2014, 18, s. 210–211.
- 48 Man, L. – Goudar, R. K.: Reversal of cardiomyopathy with tocilizumab in a case of HIV-negative Castleman's disease. *Eur J Haematol*, 2013, 91, s. 273–276.
- 49 Otani, N. – Morishita, Y. – Oh, I., et al.: Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab). *Intern Med*, 2012, 51, s. 1375–1378.
- 50 Liu, Y. C. – Stone, K. – van Rhee, F.: Siltuximab for multicentric Castleman disease. *Expert Rev Hematol*, 2014, s. 1–13.
- 51 van Rhee, F. – Fayad, L. – Voorhees, P., et al.: Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. *J Clin Oncol*, 2010, 28, s. 3701–3708.
- 52 Kurzrock, R. – Voorhees, P. M. – Casper, C., et al.: A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. *Clin Cancer Res*, 2013, 19, s. 3659–3670.
- 53 Van Rhee, F. – Wong, R. S. – Munshi, N., et al.: Siltuximab for multicentric Castleman's disease. A randomized double blind placebo controlled trial. *Lancet Oncol*, 2014, 15, s. 966–974.
- 54 Van Rhee, F. – Casper, C. – Voorhees, P. M., et al.: Phase 2 open labeled multicenter study of long term safety of siltuximab in patients with multicentric Castleman's disease. *Oncotarget*, 2015, 6, s. 30408–30419.
- 55 van Rhee, F. – Casper, C. – Voorhees, P. M., et al.: Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. *Lancet Haematol*, 2020, 7, s. e209–e217.
- 56 Galeotti, C. – Tran, T. A. – Franchi-Abella, S., et al.: IL-1RA agonist (anakinra) in the treatment of multifocal castelman disease: case report. *J Pediatr Hematol Oncol*, 2008, 30, s. 920–924.
- 57 El-Osta, H. – Janku, F. – Kurzrock, R.: Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). *Mol Cancer Ther*, 2010, 9, s. 1485–1488.
- 58 Jouvray, M. – Terriou, L. – Meignin, V., et al.: Pseudo-Addill's disease, anasarca, thrombotic thrombocytopenic purpura and dysautonomia: An atypical presentation of multicentric Castleman's disease. Discussion of TAFRO syndrome. *Rev Med Interne*, 2016, 37, s. 53–57.
- 59 Yamaga, Y. – Tokuyama, K. – Kato, T., et al.: Successful treatment with cyclosporin A in tocilizumab-resistant TAFRO syndrome. *Intern Med*, 2016, 55, s. 185–190.
- 60 Inoue, M. – Ankou, M. – Hua, J., et al.: Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. *J Clin Exp Hematol*, 2013, 53, s. 95–99.
- 61 Shirai, T. – Onishi, A. – Waki, D., et al.: Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review. *Medicine*, 2018, 97, s. e11045.
- 62 Takasawa, N. – Sekiguchi, Y. – Takahashi, T., et al.: A case of TAFRO syndrome, a variant of multicentric Castleman's disease, successfully treated with corticosteroid and cyclosporine A. *Mod Rheumatol*, 2019, 29, s. 198–202.
- 63 Repetto, L. – Jaiprakash, M. P. – Selby, P. J., et al.: Aggressive angiofollicular lymph node hyperplasia (Castleman's disease) treated with high dose melphalan and autologous bone marrow transplantation. *Hematol Oncol*, 1986, 4, s. 213–217.
- 64 Ganti, A. K. – Pipinos, I. – Culcea, E., et al.: Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. *Am J Hematol*, 2005, 79, s. 206–210.
- 65 Tal, Y. – Haber, G. – Cohen, M. J., et al.: Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant. 1. *Int J Hematol*, 2011, 93, s. 677–680.
- 66 Bandera, B. – Ainsworth, C. – Shikle, J., et al.: Treatment of unicentric Castleman disease with neoadjuvant rituximab. *Chest*, 2010, 138, s. 1239–1241.
- 67 van Rhee, F. – Oksenhendler, E. – Srkalovic, G., et al.: International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. *Blood Adv*, 2020, 4, s. 6039–6050.

Zkušenosti s preparátem Adynovi

MUDr. Gabriela Romanová Oddělení klinické hematologie FN Brno, Lékařská fakulta Masarykovy univerzity, Brno

- 1 Lane, S.: Haemorrhagic diathesis: successful transfusion of blood. *Lancet*, 1840, 35, s. 185–188.
- 2 Lambert, T. – Benson, G. – Dolan, G., et al.: Practical aspects of extended half-life products for the treatment of haemophilia. *Ther Adv Hematol*, 2018, 9, s. 295–308.
- 3 ADYNOVI Summary of Product Characteristics. European Medicines Agency, duben 2018. Dostupné z: <https://www.ema.europa.eu/en/medicines/human/EPAR/adynovi, vyhledáno 14. 4. 2021>.
- 4 Konkle, B. A. – Stasyshyn, O. – Chowdary, P., et al.: Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. *Blood*, 2015, 126, s. 1078–1085.
- 5 Mullins, E. S. – Stasyshyn, O. – Alvares-Roman, M. T., et al.: Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe hemophilia A. *Haemophilia*, 2017, 23, s. 238–246.
- 6 Ljung, R. – Auerswald, G. – Benson, G., et al.: Novel coagulation factor concentrates issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. *Haemophilia*, 2013, 19, s. 481–486.

Eltrombopag ve druhé linii léčby u pacienta s chronickou imunitní trombocytopenií

MUDr. Miroslav Genský Oddělení klinické hematologie, Krajská nemocnice Liberec, a. s.

- 1 Kozák, T., et al.: Doporučení ČHS pro diagnostiku a léčbu imunitní trombocytopenie (ITP). *Transfúze a hematologie dnes*, 2017, 23, s. 158–169.
- 2 Souhrnná informace o přípravku (SPC) Revolade. Státní ústav pro kontrolu léčiv, 2020, Praha, www.sukl.cz, vyhledáno 15. 4. 2021.
- 3 Doubek, M., et al.: *Léčebné postupy v hematologii 2020*. Praha, Česká hematologická společnost České lékařské společnosti J. E. Purkyně, 2020.
- 4 Vydra, J., et al.: *Hematologie v kostce*. Praha, Mladá fronta, 2019.

Léčba ravulizumabem v klinické praxi

MUDr. Libor Červinek, Ph.D. Interní hematologická a onkologická klinika Fakultní nemocnice Brno

- 1 Lee, J. W. – Sicre de Fontbrune, F. – Wong Lee Lee, L., et al.: Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. *Blood*, 2019, 133, s. 530–539.
- 2 Kulasekararaj, A. G. – Hill, A. – Rottinghaus, S. T., et al.: Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood*, 2019, 133, s. 540–549.
- 3 Brodsky, R. A. – de Latour, R. P. – Rottinghaus, S. T., et al.: Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. *Haematologica*, 2021, 106, s. 230–237, doi.org/10.3324/haematol.2019.236877.

První zkušenosti s náhradou eculizumabu ravulizumabem v léčbě klasické paroxysmální noční hemoglobinurie

MUDr. Jaromír Gumulec Klinika hematookologie FN Ostrava a Lékařské fakulty Ostravské univerzity

MUDr. Radomíra Hrdličková Klinika hematookologie FN Ostrava a Lékařské fakulty Ostravské univerzity, Krevní centrum FN Ostrava

Mgr. Jan Martinek Zdravotní ústav se sídlem v Ostravě

- 1 Devalet, B. – Mullier, F. – Chatelain, B., et al.: Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. *Eur J Haematol*, 2015, 95, s. 190–198.
- 2 Socié, G. – Mary, J. Y. – de Gramont, A., et al.: Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. *French Society of Haematology. Lancet*, 1996, 348, s. 573–577.
- 3 Rollins, S. A. – Sims, P. J.: The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. *J Immunol*, 1990, 144, s. 3478–3483.
- 4 Jankowska, A. M. – Szpurka, H. – Calabro, M., et al.: Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria. *Haematologica*, 2011, 96, s. 954–962.
- 5 Hugel, B. – Socié, G. – Vu, T., et al.: Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. *Blood*, 1999, 93, s. 3451–3456.
- 6 Wiedmer, T. – Hall, S. E. – Ortel, T. L., et al.: Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. *Blood*, 1993, 82, s. 1192–1196.
- 7 Moyo, V. M. – Mukhina, G. L. – Garrett, E. S., et al.: Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. *Br J Haematol*, 2004, 126, s. 133–138.
- 8 Hillmen, P. – Muus, P. – Duhrsen, U., et al.: Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. *Blood*, 2007, 110, s. 4123–4128.
- 9 Seregina, E. A. – Tsvetaeva, N. V. – Nikulina, O. F., et al.: Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria. *Blood Cells Mol Dis*, 2015, 54, s. 144–150.
- 10 Macrae, F. L. – Peacock-Young, B. – Bowman, P., et al.: Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. *Am J Hematol*, 21. 4. 2020, doi: 10.1002/ajh.25841.
- 11 Lee, J. W. – Sicre de Fontbrune, F., et al.: Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. *Blood*, 2019, 133, s. 530–539.
- 12 Kulasekararaj, A. G. – Hill, A. – Rottinghaus, S. T., et al.: Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood*, 2019, 133, s. 540–549.
- 13 Brodsky, R. A. – Peffault de Latour, R. – Rottinghaus, S. T., et al.: Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. *Haematologica*, 2021, 106, s. 230–237.
- 14 Roth, A. – Rottinghaus, S. T. – Hill, A., et al.: Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. *Blood Adv*, 2018, 2, s. 2176–2185.

Podávání eculizumabu v těhotenství

MUDr. Jan Válka, Ph.D. | prof. MUDr. Jaroslav Čermák, CSc. Ústav hematologie a krevní transfúze, Praha

- 1 Brodsky, R.: Paroxysmal nocturnal hemoglobinuria. In: Hoffman, R., et al. (eds.): *Hematology-Basic Principles and Practices*. Philadelphia, PA: Elsevier Churchill Livingstone, 2005, s. 419–427.
- 2 Weitz, I. – Meyers, G. – Lamy, T., et al.: Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria. *Intern Med J*, 2013, 43, s. 298–307.
- 3 Bais, J. – Pel, M. – von dem Borne, A. – van der Lelie, H.: Pregnancy and paroxysmal nocturnal hemoglobinuria. *Eur J Obstet Gynecol*, 1994, 53, s. 211–214.
- 4 Bjorge, L. – Ernst, P. – Haram, K. O.: Paroxysmal nocturnal hemoglobinuria in pregnancy. *Acta Obstetrica et Gynecologica Scandinavica*, 2003, 82, s. 1067–1071.
- 5 Fieni, S., et al.: Clinical management of paroxysmal nocturnal hemoglobinuria in pregnancy: a case report and updated review. *Obstet Gynecol Surv*, 2006, 61, s. 593–601.
- 6 Spencer, J. A. D.: Paroxysmal nocturnal hemoglobinuria in pregnancy: case report. *Br J Obstet Gynaecol*, 1980, 87, s. 246–248.
- 7 Ray, J., et al.: Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. *Hemostasis*, 2000, 30, s. 103–117.
- 8 Tichelli, A. – Socie, G. – Marsh, J., et al.: Outcome of pregnancy and disease course among women with aplastic anaemia treated with immunosuppression. *An Intern Med*, 2002, 137, s. 164–172.
- 9 de Guibert, S., et al.: Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience. *Hematologica*, 2011, 96, s. 1276–1283.
- 10 Sarno, L., et al.: Eculizumab in pregnancy: a narrative overview. *J Nephrol*, 2019, 32, s. 17–25.
- 11 Kelly, R. J., et al.: Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. *N Engl J Med*, 2015, 373, s. 1032–1039.
- 12 Hallstensen, R. F., et al.: Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. *Immunobiology*, 2015, 220, s. 452–459.

Erdheimova-Chesterova choroba – zánětlivé projevy, které indukuje maligní choroba – diagnostika a léčba

prof. MUDr. Zdeněk Adam, CSc. | prof. MUDr. Marta Krejčí, Ph.D. | prof. MUDr. Luděk Pour, Ph.D. | MUDr. Martin Krejčí |

MUDr. Martin Štork, Ph.D. | MUDr. Zdeněk Král, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno

doc. MUDr. Zdeněk Řehák, Ph.D. | MUDr. Renata Koukalová Oddělení nukleární medicíny, Masarykův onkologický ústav, Brno

doc. RNDr. Sabina Ševčíková, Ph.D. Ústav patologické fyziologie LF MU a FN Brno

MUDr. Tomáš Nebeský, CSc. Klinika zobrazovacích metod LF MU a FN Brno

MUDr. Zuzana Adamová, Ph.D. Chirurgické oddělení, Vsetínská nemocnice

- Chester, W.: Über Lipoidgranulomatose. *Virchows Arch Pathol Anat*, 1930, 279, s. 561–602.
- Haroche, J. – Cohen-Aubart, F. – Amoura, Z.: Erdheim-Chester disease. *Blood*, 2020, 135, s. 1311–1318.
- Diamond, E. – Dogna, L. – Hyman, D. M., et al.: Consensus guidelines for diagnosis and clinical management of Erdheim-Chester disease. *Blood*, 2014, 124, s. 483–492.
- Goyal, G. – Heaney, M. L. – Collin, M., et al.: Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. *Blood*, 2020, 135, s. 1929–1945.
- Haroche, J. – Poulain, S. – Marceau-Renaud, A., et al.: Clonal hematopoiesis in Erdheim-Chester Disease. *Blood*, 2017, 130, s. 3788–3779.
- Cohen-Aubart, F. – Emile, J.-F. – Carrat, F., et al.: Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. *Am J Hematol*, 2018, 93, s. E114–E117.
- Estrada-Veras, J. I. – O'Brien, K. J. – Boyd, L. C., et al.: The clinical spectrum of Erdheim-Chester disease: an observational cohort study. *Blood Adv*, 2017, 1, s. 357–366.
- He, T. – Cui, L. – Niu, N., et al.: Bone mineral density and bone microarchitecture in a cohort of patients with Erdheim-Chester Disease. *Orphanet J Rare Dis*, 2020, 15, s. 236.
- Lachenal, F. – Cotton, F. – Desmurs-Clavel, H., et al.: Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. *J Neurol*, 2006, 253, s. 1267–1277.
- Drier, A. – Haroche, J. – Savatovsky, J., et al.: Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. *Radiology*, 2010, 255, s. 586–594.
- Courtilot, C. – Laugier Robiolle, S., et al.: Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester disease. *J Clin Endocrinol Metab*, 2016, 101, s. 305–313.
- Peisen, F. – Thaïss, W. M. – Eckert, K., et al.: Retroperitoneal fibrosis and its differential diagnoses: the role of radiological imaging. *Rofo*, 2020, 192, s. 929–936.
- Sanchez-Nadales, A. – Anampa-Guzman, A. – Navarro-Motta, J.: Erdheim-Chester disease with extensive pericardial involvement: a case report and systematic review. *Cardiol Res*, 2020, 11, s. 118–128.
- Chasset, F. – Barette, S. – Charlotte, F., et al.: Cutaneous manifestations of Erdheim-Chester disease (ECD): clinical, pathological, and molecular features in a monocentric series of 40 patients. *J Am Acad Dermatol*, 2016, 74, s. 513–520.
- Haroche, J. – Cohen-Aubart, F. – Rollins, B. J.: Histiocytoses: emerging neoplasia behind inflammation. *Lancet Oncol*, 2017, 18, s. e113–e125.
- Papo, M. – Emile, J. F. – Maciel, T. T., et al.: Erdheim-Chester disease: a concise review. *Curr Rheumatol Rep*, 2019, 21, s. 66.
- Jendro, M. C. – Zeidler, H. – Rosenthal, H., et al.: Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil. *Clin Rheumatol*, 2004, 23, s. 52–56.
- Broccoli, A. – Stefoni, V. – Faccioli, L., et al.: Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. *Rheumatol Int*, 2012, 32, s. 2209–2213.
- Jeon, I. S. – Lee, S. S. – Lee, M. K.: Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. *Pediatr Blood Cancer*, 2010, 55, s. 745–747.
- Bourke, S. C. – Nicholson, A. G. – Gibson, G. J.: Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone. *Thorax*, 2003, 58, s. 1004–1005.
- Yano, S. – Kobayashi, K. – Kato, K., et al.: A case of Erdheim-Chester disease effectively treated by cyclophosphamide and prednisolone. *Nihon Kokyuki Gakkai Zasshi*, 2007, 45, s. 43–48.
- Gaspar, N. – Boudou, P. – Haroche, J., et al.: High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. *Haematologica*, 2006, 91, s. 1121–1125.
- Boissel, N. – Wechsler, B. – Leblond, V.: Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. *Ann Intern Med*, 2001, 135, s. 844–845.
- Cao, X. X. – Niu, N. – Sun, J., et al.: Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease. *Ann Hematol*, 2018, 97, s. 185–187.
- Wang, J. N. – Qiu, Y. – Niu, N., et al.: Successful treatment of central nervous system involved Erdheim-Chester disease by intermediate-dose cytarabine as first-line therapy. *Acta Oncol*, 2020, 59, s. 302–305.
- Mascalchi, M. – Nencini, P. – Nistri, M., et al.: Failure of radiation therapy for brain involvement in Erdheim-Chester disease. *J Neurooncol*, 2002, 59, s. 169–172.
- Katsunori, M. – Yasushi, N. – Masahiro, H.: Radiotherapy for Erdheim-Chester disease. *Int J Clin Oncol*, 2007, 12, s. 238–241.
- Chicas Sett, R. – Pons Llanas, O. – Celada Alvarez, F.: A case report of recurrent adult-onset xanthogranuloma: is the radiotherapy a treatment option? *Int Cancer Conf J*, 2015, 5, s. 77–81.
- Blomstrand, L. – Thor, A. – Hagberg, H.: Erdheim-Chester disease presenting as periodontal disease: Experience of treatment with cladribine, interferon- α , local radiotherapy and anakinra. *Acta Oncol*, 2016, 55, s. 248–250.
- Matsui, K. – Nagata, Y. – Hiraoka, M.: Radiotherapy for Erdheim-Chester disease. *Int J Clin Oncol*, 2007, 12, s. 238–241.
- Miller, R. – Villá, S. – Kamer, S., et al.: Palliative treatment of Erdheim-Chester disease with radiotherapy: a rare cancer network study. *Radiation Oncol*, 2006, 80, s. 323–326.
- Sivak-Calcot, J. – Rootman, J. – Rasmussen, S., et al.: Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review. *Br J Ophthalmol*, 2006, 90, s. 602–608.
- Veysier-Belot, C. – Cacoub, P. – Caparros-Lefebvre, D., et al.: Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. *Medicine*, 2001, 75, s. 157–169.
- Singh, V. – Prajeeth, C. K. – Gudi, V., et al.: 2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. *Clin Exp Immunol*, 2013, 173, s. 288–297.
- Goyal, G. – Ravindran, A. – Young, J. R., et al.: Mayo Clinic Histiocytosis Working Group: Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. *Haematologica*, 2020, 105, s. 348–357.
- Adam, Z. – Řehák, Z. – Koukalová, R., et al.: PET-CT dokumentovaná kompletní 4letá remise Erdheimovy-Chesterovy nemoci po léčbě cladribinem. *Vnitřní Léč*, 2014, 60, s. 499–511.
- Azadeh, N. – Tazelaar, H. D. – Gotway, M. B., et al.: Erdheim-Chester Disease treated successfully with cladribine. *Respir Med Case Rep*, 2016, 18, s. 37–40.
- Myra, C. – Sloper, L. – Tighe, P. J., et al.: Treatment of Erdheim-Chester disease with cladribine: a rational approach. *Br J Ophthalmol*, 2004, 88, s. 844–847.
- Perić, P. – Antić, B. – Knezević-Usaj, S., et al.: Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis. *Vojnosanit Pregl*, 2016, 73, s. 83–87.
- Rajendra, B. – Duncan, A. – Parslew, R., et al.: Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. *Pediatr Blood Cancer*, 2009, 52, s. 413–415.
- Sheidow, T. G. – Nicolle, D. A. – Heathcote, J. G.: Erdheim-Chester disease: two cases of orbital involvement. *Eye (Lond)*, 2000, 14, s. 606–612.
- Sutton, L. – Sutton, S. – Sutton, M.: Treatment of necrobiotic xanthogranuloma with 2-chlorodeoxyadenosine. *Skinmed*, 2013, 11, s. 121–123.
- Tamura, S. – Kawamoto, K. – Miyoshi, H., et al.: Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report. *J Clin Exp Hematol*, 2018, 58, s. 161–165.
- Goyal, G. – Shah, M. V. – Call, T. G., et al.: Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease. *JAMA Oncol*, 2017, 3, s. 1253–1256.
- Esmaili, B. – Ahmadi, A. – Tang, R., et al.: Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. *Am J Ophthalmol*, 2001, 132, s. 945–947.
- Braiteh, F. – Boxrud, C. – Esmaili, B., et al.: Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon- α . *Blood*, 2005, 106, s. 2992–2994.
- Suzuki, H. I. – Hosoya, N. – Miyagawa, K., et al.: Erdheim-Chester disease: multisystem involvement and management with interferon- α . *Leuk Res*, 2010, 34, s. e21–e24.
- Haroche, J. – Amoura, Z. – Trad, S. G., et al.: Variability in the efficacy of interferon- α in Erdheim-Chester disease by patient and site of involvement: results in eight patients. *Arthritis Rheum*, 2006, 54, s. 3330–3336.
- Hervier, B. – Arnaud, L. – Charlotte, F., et al.: Treatment of Erdheim-Chester disease with long-term high-dose interferon- α . *Semin Arthritis Rheum*, 2012, 41, s. 1–7.
- Arnaud, L. – Hervier, B. – Neel, A., et al.: CNS involvement and treatment with interferon- α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. *Blood*, 2011, 117, s. 2778–2782.
- Bulycheva, E. N. – Baykov, V. V. – Zarskij, M. I., et al.: Rare form of Erdheim-Chester disease presenting with isolated central skeletal lesions treated with a combination of alpha-interferon and zoledronic acid. *Case Rep Hematol*, 2015, 2015, s. 876752.
- Suzuki, H. I. – Hosoya, N. – Miyagawa, K., et al.: Erdheim-Chester disease: multisystem involvement and management with interferon- α . *Leuk Res*, 2010, 34, s. e21–e24.
- Tezol, O. – Citak, E. C. – Ayhan, Y. S., et al.: Effective High-dose interferon- α therapy in a 13-year-old girl with Erdheim-Chester disease. *J Pediatr Hematol Oncol*, 2020, 42, s. 326–331.
- Aouba, A. – Georjina-Lavialle, S. – Pagnoux, C., et al.: Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. *Blood*, 2010, 116, s. 4070–4076.
- Podestà, M. A. – Graziani, G. – Reggiani, F., et al.: Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra. *Kidney Res Clin Pract*, 2014, 33, s. 165–167.
- Sturtz, P. – Adam, Z. – Řehák, Z., et al.: Xanthelasma palpebrarum responding to interleukin-1 blockade. *Intern Med J*, 2014, 44, s. 617–618.
- Darstein, F. – Kirschev, S. – Heckl, S., et al.: Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids. *Intern Med J*, 2014, 44, s. 90–92.
- Courcou, A. – Vignot, E. – Chapurlat, R.: Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. *Joint Bone Spine*, 2014, 81, s. 175–177.
- Killu, A. M. – Liang, J. J. – Jaffe, A. S.: Erdheim-Chester disease with cardiac involvement successfully treated with anakinra. *Int J Cardiol*, 2013, 167, s. e115–e117.
- Aubert, O. – Aouba, A. – Deshayes, S., et al.: Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra. *Joint Bone Spine*, 2013, 80, s. 206–207.
- Tran, T. A. – Pariate, D. – Lecron, J. C., et al.: Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs. *Arthritis Rheum*, 2011, 63, s. 4031–4032.
- Cohen-Aubart, F. – Maksud, P. – Saadoun, D., et al.: Variability in the efficacy of the IL-1 receptor antagonist anakinra for treating Erdheim-Chester disease. *Blood*, 2016, 127, s. 1509–1512.
- Goyal, G. – Shah, M. V. – Call, T. G., et al.: Efficacy of biological agents in the treatment of Erdheim-Chester disease. *Br J Haematol*, 2018, 183, s. 520–524.
- Franconieri, F. – Deshayes, S. – de Boysson, H., et al.: Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment. *Oncotarget*, 2018, 7, s. e1450712.
- Dagna, L. – Corti, A. – Langheim, S., et al.: Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. *J Clin Oncol*, 2012, 30, s. e286–e290.
- Ferrero, E. – Belloni, D. – Corti, A., et al.: TNF- α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. *Rheumatology*, 2014, 53, s. 198–200.
- Goyal, G. – Shah, M. V. – Call, T. G., et al.: Efficacy of biological agents in the treatment of Erdheim-Chester disease. *Br J Haematol*, 2018, 183, s. 520–524.
- Cohen-Aubart, F. – Maksud, P. – Emile, J.-F., et al.: Efficacy of infliximab in the treatment of Erdheim-Chester disease. *Ann Rheum Dis*, 2018, 77, s. 1387–1390.
- Jia, X. – Ning, X. – Bai, Q., et al.: Combination of adalimumab with lower dose of methylprednisolone in Erdheim-Chester disease with systemic involvement. *Acta Oncol*, 2017, 56, s. 753–756.

- 70 Haroche, J. – Amoura, Z. – Charlotte, F., et al.: Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. *Blood*, 2008, 111, s. 5413–5415.
- 71 Montella, L. – Insabato, L. – Palmieri, G.: Imatinib mesylate for cerebral Langerhans-cell histiocytosis. *N Engl J Med*, 2004, 351, s. 1034–1035.
- 72 Utikal, J. – Ugurel, S. – Kurzen, H., et al.: Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. *Arch Dermatol*, 2007, 143, s. 736–740.
- 73 Haroche, J. – Charlotte, F. – Arnaud, L., et al.: High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. *Blood*, 2012, 27, s. 2700–2703.
- 74 Haroche, J. – Cohen-Aubart, F. – Emile, J. F., et al.: Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. *Blood*, 2013, 121, s. 1495–1500.
- 75 Hyman, D. M. – Puzanov, I. – Subbiah, V., et al.: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. *N Engl J Med*, 2015, 373, s. 726–736.
- 76 Diamond, E. L. – Durham, B. H. – Haroche, J., et al.: Diverse and targetable kinase alterations drive histiocytic neoplasms. *Cancer Discov*, 2016, 6, s. 154–165.
- 77 Emile, J.-F. – Diamond, E. L. – Hélias-Rodzewicz, Z., et al.: Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. *Blood*, 2014, 124, s. 3016–3019.
- 78 Cohen-Aubart, F. – Emile, J. F. – Maksud, P., et al.: Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. *Neurology*, 2014, 83, s. 1294–1296.
- 79 Diamond, E. L. – Durham, B. H. – Ulaner, G. A., et al.: Efficacy of MEK inhibition in patients with histiocytic neoplasms. *Nature*, 2019, 567, s. 521–524.
- 80 Eusirchen, P. – Haroche, J. – Emile, J. F., et al.: Complete remission of critical neurohistiocytosis by vemurafenib. *Neurol Neuroimmunol Neuroinflamm*, 2015, 2, s. e78.
- 81 Franconieri, F. – Martin-Silva, N. – de Boysson, H., et al.: Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies. *Acta Oncol*, 2016, 55, s. 930–930.
- 82 Haroche, J. – Cohen-Aubart, F. – Emile, J. F., et al.: Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. *J Clin Oncol*, 2015, 33, s. 411–418.
- 83 Schirmer, J. H. – Thorns, C. – Moosig, F., et al.: Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib. *Rheumatology*, 2015, 54, s. 1932–1934.
- 84 Tzoulis, C. – Schwarzlmüller, T. – Gjerde, I. O., et al.: Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. *BMC Res Notes*, 2015, 8, s. 171.
- 85 Oneal, P. A. – Kwitkowski, V. – Luo, L., et al.: FDA Approval Summary: Vemurafenib for the treatment of patients with Erdheim-Chester disease with the BRAFV600 mutation. *Oncologist*, 2018, 23, s. 1520–1524.
- 86 Diamond, E. L. – Subbiah, V. – Lockhart, A. C., et al.: Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. *JAMA Oncol*, 2018, 4, s. 384–388.
- 87 Cohen Aubart, F. – Emile, J.-F. – Carat, F., et al.: Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVEstudy). *Blood*, 2017, 130, s. 1377–1380.
- 88 Bhatia, A. – Hatzoglou, V. – Ulaner, G., et al.: Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. *Neuro Oncol*, 17. 1. 2020, doi:10.1093/neuonc/noaa008.
- 89 Grob, J. J. – Amonkar, M. M. – Karaszewska, B.: Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. *Lancet Oncol*, 2015, 16, s. 1389–1398.
- 90 Al Bayati, A. – Plate, T. – Al Bayati, M., et al.: Dabrafenib and trametinib treatment for Erdheim-Chester disease with brain stem involvement. *Mayo Clin Proc Innov Qual Outcomes*, 2018, 2, s. 303–308.
- 91 Sanders, I. M. – Goodman, A. – Kurzrock, R.: Real world toxicity experience with BRAF/MEK inhibitors in patients with Erdheim-Chester disease. *Oncologist*, 2019, 24, s. 1–5.
- 92 Campochiaro, C. – Cavalli, G. – Farina, N., et al.: Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. *Ann Rheum Dis*, 9. 12. 2019, doi: 10.1136/annrheumdis-2019-216610.
- 93 Fernández-Eulate, G. – Muñoz-Lopetegui, A. – Ruiz, I., et al.: Vemurafenib as first-line therapy in BRAF-V600E-mutant Erdheim-Chester disease with CNS involvement. *BMJ Case Rep*, 2019, 12, pii: e228280.
- 94 Van Keerberghen, C. A. – Harrouk, A. – Leone, L.: A new role for fluorine-18-fluorodeoxyglucose positron-emission tomography/computed tomography in Erdheim-Chester disease. *World J Nucl Med*, 2019, 18, s. 201–203.
- 95 Akin, E. A. – Osman, M. – Ellenbogen, A. L.: FDG PET/CT findings of Erdheim-Chester disease: radiologic response to a novel treatment regimen. *Clin Nucl Med*, 2018, 43, s. 337–340.
- 96 Young, J. R. – Johnson, G. B. – Murphy, R. C., et al.: (18)F-FDG PET/CT in Erdheim-Chester disease: imaging findings and potential BRAF mutation biomarker. *J Nucl Med*, 2018, 59, s. 774–779.
- 97 Řehák, Z. – Koukalová, R. – Vašina, J., et al.: 18F-FDG PET/CT obraz Erdheimovy-Chesterovy nemoci – přehled českých pacientů. *Nukleární medicína*, 2018, 7, s. 50–56.
- 98 Wang, W. X. – Cheng, Z. T. – Zhu, J. L., et al.: Combined clinical parameters improve the diagnostic efficacy of ¹⁸F-FDG PET/CT in patients with fever of unknown origin (FUO) and inflammation of unknown origin (IUO): A prospective study in China. *Int J Infect Dis*, 2020, 93, s. 77–83.
- 99 Georga, S. – Exadaktylou, P. – Petrou, I., et al.: Diagnostic Value of 18F-FDG-PET/CT in Patients with FUO. *J Clin Med*, 2020, 9, s. 2112.
- 100 Pijl, J. P. – Kwee, T. C. – Legger, G. E., et al.: Role of FDG-PET/CT in children with fever of unknown origin. *Eur J Nucl Med Mol Imaging*, 2020, 47, s. 1596–1604.